Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
60
LMAT Quote, Financials, Valuation and Earnings
Last price:
$108.31
Seasonality move
:
9.89%
Day range:
$105.51 - $109.41
52-week range:
$71.42 - $115.33
Dividend yield:
0.79%
P/E ratio:
42.98x
P/S ratio:
10.08x
P/B ratio:
6.25x
Volume:
140.4K
Avg. volume:
297K
1-year change:
25.25%
Market cap:
$2.5B
Revenue:
$249.6M
EPS (TTM):
$2.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
$66.7M | $0.66 | 11.19% | 37.01% | $111.22 |
|
GMED
Globus Medical, Inc.
|
$740.3M | $0.92 | 23.77% | 70.28% | $110.08 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.6B | $2.13 | 16.31% | 10.98% | $605.08 |
|
OSUR
OraSure Technologies, Inc.
|
$27.7M | -$0.16 | -7.54% | -23.59% | $5.00 |
|
PRCT
PROCEPT BioRobotics Corp.
|
$80.5M | -$0.57 | 16.62% | -22.63% | $30.44 |
|
PSTV
Plus Therapeutics, Inc.
|
$974K | -$0.81 | -8.03% | -97.28% | $146.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
$108.49 | $111.22 | $2.5B | 42.98x | $0.25 | 0.79% | 10.08x |
|
GMED
Globus Medical, Inc.
|
$87.92 | $110.08 | $11.9B | 22.39x | $0.00 | 0% | 4.11x |
|
ISRG
Intuitive Surgical, Inc.
|
$452.07 | $605.08 | $156.3B | 55.87x | $0.00 | 0% | 15.86x |
|
OSUR
OraSure Technologies, Inc.
|
$3.08 | $5.00 | $215.4M | 26.67x | $0.00 | 0% | 1.99x |
|
PRCT
PROCEPT BioRobotics Corp.
|
$25.12 | $30.44 | $1.4B | -- | $0.00 | 0% | 4.48x |
|
PSTV
Plus Therapeutics, Inc.
|
$3.56 | $146.88 | $22.3M | -- | $0.00 | 0% | 3.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
32.05% | -1.308 | 10.05% | 10.85x |
|
GMED
Globus Medical, Inc.
|
2.55% | -0.963 | 1.01% | 2.55x |
|
ISRG
Intuitive Surgical, Inc.
|
0.95% | 0.639 | 0.08% | 3.73x |
|
OSUR
OraSure Technologies, Inc.
|
10.72% | 0.248 | 24.02% | 5.57x |
|
PRCT
PROCEPT BioRobotics Corp.
|
17.66% | -0.136 | 4.43% | 5.64x |
|
PSTV
Plus Therapeutics, Inc.
|
17.04% | 1.919 | 1.16% | 1.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LMAT
LeMaitre Vascular, Inc.
|
$46.2M | $18.8M | 10.5% | 15.86% | 29.22% | $21.4M |
|
GMED
Globus Medical, Inc.
|
$536M | $181.6M | 11.94% | 12.49% | 21.98% | $202.3M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.53% | 16.59% | 30.16% | $730M |
|
OSUR
OraSure Technologies, Inc.
|
$11M | -$16.9M | -17.29% | -18.18% | -62.97% | -$9.9M |
|
PRCT
PROCEPT BioRobotics Corp.
|
$46.3M | -$31M | -20.6% | -24.85% | -40.64% | -$12.2M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$5.7M | -- | -- | -420.04% | -$6.3M |
LeMaitre Vascular, Inc. vs. Competitors
-
Which has Higher Returns LMAT or GMED?
Globus Medical, Inc. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of 17.01%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat Globus Medical, Inc.'s return on equity of 12.49%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M GMEDGlobus Medical, Inc.64.85% $1.03 $4.7B -
What do Analysts Say About LMAT or GMED?
LeMaitre Vascular, Inc. has a consensus price target of $111.22, signalling upside risk potential of 2.52%. On the other hand Globus Medical, Inc. has an analysts' consensus of $110.08 which suggests that it could grow by 25.21%. Given that Globus Medical, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Globus Medical, Inc. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 4 0 GMEDGlobus Medical, Inc.6 4 0 -
Is LMAT or GMED More Risky?
LeMaitre Vascular, Inc. has a beta of 0.672, which suggesting that the stock is 32.831% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.928%.
-
Which is a Better Dividend Stock LMAT or GMED?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 0.79%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.77% of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or GMED?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are smaller than Globus Medical, Inc. quarterly revenues of $826.4M. LeMaitre Vascular, Inc.'s net income of $15.6M is lower than Globus Medical, Inc.'s net income of $140.6M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 42.98x while Globus Medical, Inc.'s PE ratio is 22.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.08x versus 4.11x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.08x 42.98x $64.5M $15.6M GMEDGlobus Medical, Inc.4.11x 22.39x $826.4M $140.6M
-
Which has Higher Returns LMAT or ISRG?
Intuitive Surgical, Inc. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of 27.89%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M ISRGIntuitive Surgical, Inc.66.41% $2.21 $18.1B -
What do Analysts Say About LMAT or ISRG?
LeMaitre Vascular, Inc. has a consensus price target of $111.22, signalling upside risk potential of 2.52%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $605.08 which suggests that it could grow by 33.85%. Given that Intuitive Surgical, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 4 0 ISRGIntuitive Surgical, Inc.17 9 1 -
Is LMAT or ISRG More Risky?
LeMaitre Vascular, Inc. has a beta of 0.672, which suggesting that the stock is 32.831% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.7%.
-
Which is a Better Dividend Stock LMAT or ISRG?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 0.79%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.77% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or ISRG?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. LeMaitre Vascular, Inc.'s net income of $15.6M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 42.98x while Intuitive Surgical, Inc.'s PE ratio is 55.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.08x versus 15.86x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.08x 42.98x $64.5M $15.6M ISRGIntuitive Surgical, Inc.15.86x 55.87x $2.9B $799.5M
-
Which has Higher Returns LMAT or OSUR?
OraSure Technologies, Inc. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of -72.06%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat OraSure Technologies, Inc.'s return on equity of -18.18%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M OSUROraSure Technologies, Inc.40.98% -$0.27 $381.7M -
What do Analysts Say About LMAT or OSUR?
LeMaitre Vascular, Inc. has a consensus price target of $111.22, signalling upside risk potential of 2.52%. On the other hand OraSure Technologies, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 62.34%. Given that OraSure Technologies, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe OraSure Technologies, Inc. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 4 0 OSUROraSure Technologies, Inc.1 2 0 -
Is LMAT or OSUR More Risky?
LeMaitre Vascular, Inc. has a beta of 0.672, which suggesting that the stock is 32.831% less volatile than S&P 500. In comparison OraSure Technologies, Inc. has a beta of 0.850, suggesting its less volatile than the S&P 500 by 15.034%.
-
Which is a Better Dividend Stock LMAT or OSUR?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 0.79%. OraSure Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.77% of its earnings as a dividend. OraSure Technologies, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or OSUR?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are larger than OraSure Technologies, Inc. quarterly revenues of $26.8M. LeMaitre Vascular, Inc.'s net income of $15.6M is higher than OraSure Technologies, Inc.'s net income of -$19.3M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 42.98x while OraSure Technologies, Inc.'s PE ratio is 26.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.08x versus 1.99x for OraSure Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.08x 42.98x $64.5M $15.6M OSUROraSure Technologies, Inc.1.99x 26.67x $26.8M -$19.3M
-
Which has Higher Returns LMAT or PRCT?
PROCEPT BioRobotics Corp. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of -39.07%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat PROCEPT BioRobotics Corp.'s return on equity of -24.85%.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M PRCTPROCEPT BioRobotics Corp.60.63% -$0.53 $444.4M -
What do Analysts Say About LMAT or PRCT?
LeMaitre Vascular, Inc. has a consensus price target of $111.22, signalling upside risk potential of 2.52%. On the other hand PROCEPT BioRobotics Corp. has an analysts' consensus of $30.44 which suggests that it could grow by 21.2%. Given that PROCEPT BioRobotics Corp. has higher upside potential than LeMaitre Vascular, Inc., analysts believe PROCEPT BioRobotics Corp. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 4 0 PRCTPROCEPT BioRobotics Corp.6 4 0 -
Is LMAT or PRCT More Risky?
LeMaitre Vascular, Inc. has a beta of 0.672, which suggesting that the stock is 32.831% less volatile than S&P 500. In comparison PROCEPT BioRobotics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LMAT or PRCT?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 0.79%. PROCEPT BioRobotics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.77% of its earnings as a dividend. PROCEPT BioRobotics Corp. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or PRCT?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are smaller than PROCEPT BioRobotics Corp. quarterly revenues of $76.4M. LeMaitre Vascular, Inc.'s net income of $15.6M is higher than PROCEPT BioRobotics Corp.'s net income of -$29.8M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 42.98x while PROCEPT BioRobotics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.08x versus 4.48x for PROCEPT BioRobotics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.08x 42.98x $64.5M $15.6M PRCTPROCEPT BioRobotics Corp.4.48x -- $76.4M -$29.8M
-
Which has Higher Returns LMAT or PSTV?
Plus Therapeutics, Inc. has a net margin of 24.18% compared to LeMaitre Vascular, Inc.'s net margin of -417.92%. LeMaitre Vascular, Inc.'s return on equity of 15.86% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LMATLeMaitre Vascular, Inc.71.67% $0.68 $579.1M PSTVPlus Therapeutics, Inc.93.27% -$0.04 $4.8M -
What do Analysts Say About LMAT or PSTV?
LeMaitre Vascular, Inc. has a consensus price target of $111.22, signalling upside risk potential of 2.52%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than LeMaitre Vascular, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LMATLeMaitre Vascular, Inc.4 4 0 PSTVPlus Therapeutics, Inc.3 1 0 -
Is LMAT or PSTV More Risky?
LeMaitre Vascular, Inc. has a beta of 0.672, which suggesting that the stock is 32.831% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.
-
Which is a Better Dividend Stock LMAT or PSTV?
LeMaitre Vascular, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 0.79%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 31.77% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LMAT or PSTV?
LeMaitre Vascular, Inc. quarterly revenues are $64.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. LeMaitre Vascular, Inc.'s net income of $15.6M is higher than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 42.98x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 10.08x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LMATLeMaitre Vascular, Inc.10.08x 42.98x $64.5M $15.6M PSTVPlus Therapeutics, Inc.3.21x -- $1.4M -$5.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
